Tirzepatide for managing overweight and obesity [ID6179]

Funding variation request

Following the Technology Appraisal Committee meeting on 13 August 2024, we are consulting with consultees and commentators on the case for extending the statutory 3-month period for funding of tirzepatide for managing overweight and obesity. Following the consultation, NICE Guidance Executive will make a final decision on whether the statutory period of funding should be extended. The final decision will be included in the Final Draft Guidance which will be issued for appeal with publication of final guidance on this appraisal anticipated in December 2024 if no appeals are received.

The request from NHS England to vary the funding requirement timeframe for implementation of the NICE committee’s final draft recommendation is included here for information.

The committee’s final recommendation on tirzepatide for managing overweight and obesity is as follows:

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity, in adults, only if they have:

• an initial body mass index (BMI) of at least 35 kg/m² and
• at least 1 weight-related comorbidity.

Use lower BMI thresholds (usually reduced by 2.5 kg/m²) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

If less than 5% of the initial weight has been lost after 6 months on the highest tolerated dose, decide whether to continue treatment, taking into account the benefits and risks of treatment for the person.